Eli Lilly said on November 18, 2025 its Board of Directors elected Carolyn R. Bertozzi, Ph.D. as a new member of the Board, effective December 8, 2025.

1. 01

   Eli Lilly said on November 18, 2025 its Board of Directors elected Carolyn R. Bertozzi, Ph.D. as a new member of the Board, effective December 8, 2025.

2. 02

   The company said Dr. Bertozzi is 59 years old and is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute.

3. 03

   Eli Lilly said Dr. Bertozzi will serve on both the Board's Science and Technology Committee and Ethics and Compliance Committee and will stand for election by shareholders at the Company's annual meeting in May 2026.

4. 04

   The company said the Board has determined that Dr. Bertozzi is independent under applicable standards of the New York Stock Exchange and the Company's director independence guidelines, there are no arrangements or understandings related to her selection, she is not a party to any transaction subject to Section 404(a) of Regulation S-K involving the Company or any of its subsidiaries, and she will participate in the Company's standard director compensation program.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.